Related Experiment Video

Updated: Jun 25, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

[Nutrition-obesity. Rimonabant and cardiovascular risk factors]

Makoundou Vincent1, Alain Golay

  • 1Service d'enseignement thérapeutique pour maladies chroniques, Département de médecine communautaire et de premier recours, HUG, 1211 Genève 14.

Revue Medicale Suisse
|February 17, 2009
PubMed

Insights

Cardiovascular disease remains a leading cause of death globally. While managing risk factors like obesity and hypertension helps, persistent issues like insulin resistance necessitate new treatments, such as the withdrawn drug Rimonabant.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Cardiovascular mortality is the leading global cause of death.
  • Key risk factors include obesity, hypertension, diabetes, and hypercholesterolemia.
  • Despite management, insulin resistance, hypo-adiponectinemia, and inflammation contribute to atherosclerosis.

Purpose of the Study:

  • To explore novel therapeutic solutions for cardiovascular risk factors.
  • To investigate the potential of Rimonabant, a CB1-blocker, in managing cardiovascular risks.
  • To highlight the need for long-term efficacy assessment of such agents.

Main Methods:

  • Review of existing literature on cardiovascular risk factors and treatments.
  • Analysis of Rimonabant's mechanism of action as a CB1-blocker.
  • Discussion of the implications of Rimonabant's market withdrawal.

Main Results:

  • Current treatments effectively manage some cardiovascular risk factors.
  • Insulin resistance, hypo-adiponectinemia, and inflammation remain significant challenges.
  • Rimonabant showed potential for managing multiple cardiovascular risk factors.

Conclusions:

  • Additional therapeutic strategies are required to address persistent cardiovascular risk factors.
  • Rimonabant's withdrawal prevented long-term assessment of its cardiovascular mortality impact.
  • Further research into similar agents may offer future therapeutic avenues.

More Related Videos

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents09:10

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents

Published on: November 1, 2019

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...